These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12181246)

  • 1. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
    Perez EA; Geeraerts L; Suman VJ; Adjei AA; Baron AT; Hatfield AK; Maihle N; Michalak JC; Kuross SA; Kugler JW; Lafky JM; Ingle JN
    Ann Oncol; 2002 Aug; 13(8):1225-35. PubMed ID: 12181246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
    Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
    Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer.
    Yazilitas D; Sendur MA; Karaca H; Ozdemir N; Aksoy S; Berk V; Yazici O; Ozturk B; Ozkan M; Zengin N; Altundag K
    Asian Pac J Cancer Prev; 2015; 16(4):1471-7. PubMed ID: 25743817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
    Khayat D; Chollet P; Antoine EC; Monfardini S; Ambrosini G; Benhammouda A; Mazen MF; Sorio R; Borg-Olivier O; Riva A; Ramazeilles C; Azli N
    J Clin Oncol; 2001 Jul; 19(14):3367-75. PubMed ID: 11454884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
    Nabholtz JM; Falkson C; Campos D; Szanto J; Martin M; Chan S; Pienkowski T; Zaluski J; Pinter T; Krzakowski M; Vorobiof D; Leonard R; Kennedy I; Azli N; Murawsky M; Riva A; Pouillart P;
    J Clin Oncol; 2003 Mar; 21(6):968-75. PubMed ID: 12637459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
    Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
    Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
    Jackisch C; von Minckwitz G; Eidtmann H; Costa SD; Raab G; Blohmer JU; Schütte M; Gerber B; Merkle E; Gademann G; Lampe D; Hilfrich J; Tulusan AH; Caputo A; Kaufmann M
    Clin Breast Cancer; 2002 Oct; 3(4):276-80. PubMed ID: 12425756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
    Ishiguro H; Masuda N; Sato N; Higaki K; Morimoto T; Yanagita Y; Mizutani M; Ohtani S; Kaneko K; Fujisawa T; Takahashi M; Kadoya T; Matsunami N; Yamamoto Y; Ohno S; Takano T; Morita S; Tanaka-Mizuno S; Toi M
    Breast Cancer Res Treat; 2020 Apr; 180(3):715-724. PubMed ID: 32170634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
    Nabholtz JM; Mackey JR; Smylie M; Paterson A; Noël DR; Al-Tweigeri T; Tonkin K; North S; Azli N; Riva A
    J Clin Oncol; 2001 Jan; 19(2):314-21. PubMed ID: 11208821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study.
    Antolín S; Mel R; Ramos M; García-Palomo A; Almanza C; de Paz L; Calvo L; Alvarez E; González A; García-Mata J
    Clin Transl Oncol; 2011 Sep; 13(9):686-91. PubMed ID: 21865141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
    Bear HD; Anderson S; Brown A; Smith R; Mamounas EP; Fisher B; Margolese R; Theoret H; Soran A; Wickerham DL; Wolmark N;
    J Clin Oncol; 2003 Nov; 21(22):4165-74. PubMed ID: 14559892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
    Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
    Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
    Perrone F; Nuzzo F; Di Rella F; Gravina A; Iodice G; Labonia V; Landi G; Pacilio C; Rossi E; De Laurentiis M; D'Aiuto M; Botti G; Forestieri V; Lauria R; De Placido S; Tinessa V; Daniele B; Gori S; Colantuoni G; Barni S; Riccardi F; De Maio E; Montanino A; Morabito A; Daniele G; Di Maio M; Piccirillo MC; Signoriello S; Gallo C; de Matteis A
    Ann Oncol; 2015 Apr; 26(4):675-682. PubMed ID: 25488686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
    Aihara T; Takatsuka Y; Itoh K; Sasaki Y; Katsumata N; Watanabe T; Noguchi S; Horikoshi N; Tabei T; Sonoo H; Hiraki S; Inaji H
    Oncology; 2003; 64(2):124-30. PubMed ID: 12566909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
    von Minckwitz G; Raab G; Caputo A; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Kaufmann M
    J Clin Oncol; 2005 Apr; 23(12):2676-85. PubMed ID: 15837982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.